Natalie McNamee

Natalie McNamee

Private Equity Investor at
Tarnagulla Ventures Pty Ltd.
Consumer Services
Health Technology
Finance

Profile

Natalie has been a Director of Tarnagulla Ventures Pty Ltd since 2015.
She had led the investment diligence into most of the portfolio companies since then, including Lubris BioPharma, a company which has since successfully licensed their lead indication to Novartis.
Prior to returning to Australia, Natalie worked for Tocagen Inc, a gene therapy company, based in San Diego, in their business development team whilst finishing her Masters.
She then worked as a bioengineer at the then-newly formed Quanticel Pharmaceuticals, a cancer stem cell focused drug developer.
Quanticel was acquired by Celgene for $485M in 2015.
Natalie received her Masters in Bioengineering at UC San Diego and a dual Bachelor of Finance and Mechanical Engineering from Melbourne University.

Natalie McNamee active positions

CompaniesPositionStart
Private Equity Investor 31/12/2014

Former positions of Natalie McNamee

Training of Natalie McNamee

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

1

1st degree connections

4

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies4

Consumer Services

Consumer Services

Health Technology

Finance

  1. Stock Market
  2. Insiders
  3. Natalie McNamee